Differential risk of remission and ESRD in childhood FSGS

被引:121
作者
Gipson, DS [1 ]
Chin, H
Presler, TP
Jennette, C
Ferris, ME
Massengill, S
Gibson, K
Thomas, DB
机构
[1] Univ N Carolina, UNC Kidney Ctr, Chapel Hill, NC 27599 USA
[2] Carolinas Med Ctr, Dept Pediat, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Pathol, Chapel Hill, NC USA
关键词
ESRD; focal segmental glomerulosclerosis; Glomerular Disease Collaborative Network; proteinuria;
D O I
10.1007/s00467-005-2097-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Focal segmental glomerulosclerosis (FSGS) is the leading cause of steroid-resistant nephrotic syndrome in childhood and the most common form of end stage renal disease (ESRD) from glomerular disease. In order to assess the risk of progression of children with primary FSGS and the impact of proteinuria remission status on disease progression, we undertook this study to describe a cohort of 60 children and adolescents from the Glomerular Disease Collaborative Network. Of the 60 patients included in the cohort, 58% were African American. Median age was 16 years. Proteinuria ranged from 1.0-24.0 g/day/1.73 m(2); 57% were hypertensive, and the median estimated glomerular filtration rate (eGFR) was 90.2 ml/min/1.73 m(2). Complete remission was achieved in 20%, partial remission in 33%, and 47% have not achieved remission during follow-up with all prescribed therapy. Only ACE-I/ARB therapy was predictive of proteinuria remission in multivariate analysis (hazard ratio [HR] 3.35; 95% confidence interval [CI] 1.42-7.92). Renal survival was much improved in patients with complete or partial remission compared with no remission in univariate analysis. In multivariate analysis comparing no remission status, complete remission was associated with a 90% decreased risk of ESRD (HR 0.10, 95% CI 0.01-0.79, p =0.03). In summary, proteinuria remission status is a valid predictor of long-term renal survival in children with FSGS.
引用
收藏
页码:344 / 349
页数:6
相关论文
共 30 条
[1]   Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis [J].
Alexopoulos, E ;
Stangou, M ;
Papagianni, A ;
Pantzaki, A ;
Papadimitriou, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (09) :1348-1356
[2]  
ALLISON PD, 1995, COMPETING RISKS, P185
[4]  
[Anonymous], STAT ANAL FAILURE TI
[5]   Enalapril dosage in steroid-resistant nephrotic syndrome [J].
Bagga, A ;
Mudigoudar, BD ;
Hari, P ;
Vasudev, V .
PEDIATRIC NEPHROLOGY, 2004, 19 (01) :45-50
[6]   FOCAL GLOMERULOSCLEROSIS - NATURAL-HISTORY AND TREATMENT - REPORT OF 70 CASES [J].
BEAUFILS, H ;
ALPHONSE, JC ;
GUEDON, J ;
LEGRAIN, M .
NEPHRON, 1978, 21 (02) :75-85
[7]  
CAMERON JS, 1978, CLIN NEPHROL, V10, P213
[8]   Management of membranous nephropathy: When and what for treatment [J].
Cattran, D .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1188-1194
[9]   Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis [J].
Cattran, D ;
Neogi, T ;
Sharma, R ;
McCarthy, ET ;
Savin, VJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (02) :448-453
[10]   Long-term outcome in children and adults with classic focal segmental glomerulosclerosis [J].
Cattran, DC ;
Rao, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :72-79